The New Frontier of Same Day Mobile Lab Diagnostics

Flambeau RapidX’s innovative mobile diagnostic testing system offers unprecedented access and high performance lab results on demand.

 
FDX_Header copy.jpg

Flambeau RapidX is one of 25 companies out of 716 competitors to win major contracts under the NIH Rapid Acceleration of Diagnostics (RADx Tech) initiative, the $500M federal program to introduce game-changing COVID-19 testing.

This project has been funded in part by the NIH Rapid Acceleration of Diagnostics (RADx) initiative with federal funds from the National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health under Contract No. 75N92020C00017. The contract is funded from the Public Health and Social Services Emergency Fund through the Biomedical Advanced Research and Development Authority, HHS Office of the Assistant Secretary for Preparedness and Response, Department of Health and Human Services.

NIH Logo

 
video-fallback.jpg

Changing the Game

When it comes to preventing and controlling outbreaks as they occur, policymakers and healthcare providers contend with significant gaps in testing capacity.

A major obstacle to this has been the absence of technologies capable of providing accurate, rapid testing in high throughput configurations with mobile capabilities.

Flambeau RapidX has developed a category defining mobile diagnostic system that bridges gaps at the point of need by delivering high performance testing with same-day results where they’re needed most.

Complete Solutions

 

point of care

centralized lab

mobile response

high accuracy

full chain of custody

time to 100 test results

time to 1000 test results

radidly adaptable

 

1600x900_FDX_Main.jpg

Redefining Mobility

Flambeau RapidX mobile units are fully contained high throughput laboratories designed to deliver best-in-class diagnostic solutions to populations where they are, when they need them.

Our systems provide the unique mobility to deploy same day, high quality testing to sites of urgent need across multiple regions, employers, and institutions with unprecedented speed, accuracy, and frequency while opening much needed access to historically underserved “healthcare deserts” and rural populations.

 

Flambeau RapidX Platform Features

mobility

Fully contained high throughput laboratories can travel to sites in urgent need and to multiple sites during daily operations

Innovation

Sample preparation and extraction, collaborative robotics

Accuracy

PCR-level sensitivity

High Throughput

Up to 1000 tests per 8 hour work shift

Rapid Results

Following one hour of setup, runtimes per batch of 40-60 minutes

Alternative Supply Chain

Primers and reagents from outside the PCR supply chain

Adaptability

Readily adaptable to multiple RNA tests, sample types and analytes

 

Pioneering Diagnostics

With demand for rapid point of need mobile testing on the rise, Flambeau RapidX was developed to offer a new approach in the delivery of laboratory services. Our proprietary technology integrates a convergence of the latest innovations—in microengineering, collaborative robotics and molecular biology—to open an entirely new product category in laboratory diagnostics.

Proprietary sample preparation and extraction technology eliminates traditional wash steps, streamlining workflows to increase throughput while elevating RT-LAMP nucleic acid amplification performance to PCR-level sensitivity.

Integrated robotics, liquid handlers, plate readers and data systems automate assays for high frequency throughput, laboratory quality performance, and same-day results in as little as one hour.

While our system was developed to focus on rapid COVID-19 pandemic response, it is readily adaptable to diagnostic tests for multiple diseases.

NIH RADX
ACCELERATION

PROPRIETARY
SAMPLE
PREP

COLLABORATIVE
ROBOTICS

LABORATORY
SYSTEMS

ADVANCED
LOGISTICS

 

About

Flambeau RapidX is inspired by technology and driven by humanity.

Flambeau RapidX emerged in response to The National Institutes of Health’s Rapid Acceleration of Diagnostics (RADx) initiative, a national call for scientists to speed innovation in the development and implementation of technologies for COVID-19 testing.

Our enabling technologies in sample preparation and analyte extraction are the culmination of a decade of biomedical engineering and disease-focused research and development at the University of Wisconsin-Madison and in the Madison healthtech cluster.

The patented Flambeau RapidX system represents a paradigm shift in laboratory diagnostics that can expand the reach of lab service providers, uniquely meet the needs of major testing networks, and provide enhanced access to underserved populations.

 Contact Us

To learn more about Flambeau RapidX, contact us at info@flambeaudx.com